Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.56 |
| ▸ | SNCA | P37840 | 2/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.53 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10924988 | 0.97 | FOLH1 (0.56) | FOLH1SNCAANPEPENPEPMEP1B | |
| Bromide SCHEMBL1532873 | 0.83 | SLC7A5 (0.60) | FOLH1SNCA | |
| Bromide SCHEMBL31614317 | 0.83 | SLC7A5 (0.60) | FOLH1SNCA | |
| Bromide SCHEMBL6524406 | 0.82 | SNCA (0.55) | SNCAANPEP | |
| Bromide SCHEMBL7025256 | 0.81 | CYP4F2 (0.56) | SNCAMEP1BKMT2A | |
| Bromide SCHEMBL5626209 | 0.81 | SNCA (0.71) | FOLH1SNCAANPEPENPEPNR4A2 | |
| Hydrochloric Acid SCHEMBL8123098 | 0.80 | SLC7A5 (0.60) | FOLH1SNCA | |
| Hydrochloric Acid SCHEMBL5149449 | 0.78 | SNCA (0.52) | SNCAANPEP | |
| Bromide SCHEMBL28707503 | 0.77 | SNCA (0.51) | SNCAANPEPKMT2A | |
| Hydrochloric Acid SCHEMBL9030893 | 0.77 | SNCA (0.68) | FOLH1SNCAANPEPENPEPNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2028155-A | — | — | None | — | — | JP | disclosed |
| EP-2639229-B9 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2639229-B1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| EP-2676955-A1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-12-25 | — | — | EP | disclosed |
| EP-2650287-A1 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2639229-A2 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R-Tech Ueno, Ltd. (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-8507690-B2 | Thiazole derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-5624943-A | Pyridine compounds which are useful as leukotriene-B4 -antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-04-29 | — | — | US | disclosed |
| EP-0651745-A1 | NEW PYRIDINE DERIVATIVES AS LEUKCOTRIENE B 4? ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-05-10 | — | — | EP | disclosed |
| US-4638002-A | ANTIAGGLOMERANTS, HYPOTENSIVE, ANTISECRETORY, ANTISPASMODIC, ANTIULCER, BRONCHODILATOR, ANTIHISTAMINES | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1987-01-20 | — | — | US | disclosed |
| EP-0155901-A1 | Carbacyclines, process for their preparation and their use as medicines | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-09-25 | — | — | EP | disclosed |
| US-4479945-A | ANTICOAGULANTS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) | 1984-10-30 | — | — | US | disclosed |
| EP-0107693-A4 | 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLIN-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1984-09-17 | — | — | EP | disclosed |
| EP-0107693-A1 | 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLIN-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1984-05-09 | — | — | EP | disclosed |
| EP-0045842-B1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM AND PROCESS FOR THE PREPARATION OF THESE HETEROCYCLIC COMPOUNDS AND MEDICAMENTS | Grünenthal GmbH (DE) | 1984-01-18 | — | — | EP | disclosed |
| WO-1983004021-A1 | 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLINE-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1983-11-24 | — | — | WO | disclosed |
| EP-0080718-A1 | Inter-m-phenylene-PGI2 derivatives, process for their preparation and pharmaceutical compositions containing them | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1983-06-08 | — | — | EP | disclosed |
| US-4372971-A | Heterocyclic prostaglandin type compounds, medicaments containing them and processes for the preparation and use of these heterocyclic compounds and medicaments | GRUENENTHAL GMBH (DE) | 1983-02-08 | — | — | US | disclosed |
| EP-0045842-A1 | Heterocyclic compounds, medicaments containing them and process for the preparation of these heterocyclic compounds and medicaments | Grünenthal GmbH (DE) | 1982-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, TAS1R1, VAPA | FOLH1 3837/4885SNCA 1355/4885ANPEP 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.